Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib versus crizotinib in treatment-naive ALK-positive advanced non-small cell lung cancer
2013-004133-33Phase 3Active
- Sponsor
- Roche
- Start
- Jun 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Alectinib with Crizotinib (2 arms). Primary endpoint: Progression-free survival. Started Jun 2014; status: active.
02
Drugs
alectinibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2013-004133-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004133-33.